Trial Profile
An 8-Week Randomized, Double-Blind, Parallel-Group, Multi-Center, Active-Controlled Dose Escalation Study to Evaluate the Efficacy and Safety of Aliskiren HCTZ (300/25 mg) Compared to Amlodipine (10 mg) in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Aliskiren/hydrochlorothiazide (Primary) ; Amlodipine
- Indications Essential hypertension; Hypertension
- Focus Biomarker; Therapeutic Use
- Acronyms ASTRIDE
- Sponsors Novartis
- 01 Dec 2011 Results published in the Journal of Clinical Hypertension (Greenwich).
- 24 Sep 2010 Results presented at the 46th Annual Meeting of the European Association for the Study of Diabetes.
- 01 May 2010 Primary endpoint 'Systolic-blood-pressure' has been met according to the results published at the 25th Annual Scientific Meeting of the American Society of Hypertension.